All In Biotech

Drug Trial Radar · NCT07755410

A Study to Evaluate Safety and Efficacy of ALKS 7290 Compared With Placebo in Adult Participants With Attention Deficit Hyperactivity Disorder (ALKS 7290-201)

A Phase 2, Randomized, Parallel-Group, Double-Blind, Study to Evaluate the Safety and Efficacy of ALKS 7290 Compared to Placebo in Adult Participants With Attention Deficit Hyperactivity Disorder

Last checked: Nov 19, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 312 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

312

Planned (sponsor's estimate)

Start

Aug 10, 2026

Primary completion

Jul 2027

Study completion Jul 2027

Sponsor

Lead sponsor
Alkermes, Inc.Industry
Sponsor type
Industry
First posted
Aug 10, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to measure safety and the improvement in symptoms in subjects with ADHD when taking ALKS 7290 tablets compared with placebo tablets.

Conditions

  • Attention Deficit Disorder With Hyperactivity (ADHD)

Interventions

  • ALKS 7290Drug

    ALKS 7290 tablets taken daily, orally, for 4 weeks

  • PlaceboDrug

    Placebo capsule taken daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from Baseline to Week 4 in Attention Deficit Disorder Investigator Symptom Rating Scale (AISRS) total scoreTime frame: Baseline to Week 4

Locations

28 sites in 1 country. Site status is shown where the registry gives one.

  • Alkermes Investigational Site

    Little Rock, Arkansas · Recruiting

  • Alkermes Investigational Site

    Chino, California · Recruiting

  • Alkermes Investigator Site

    Chino, California · Recruiting

  • Alkermes Investigational Site

    Clermont, Florida · Recruiting

  • Alkermes Investigational Site

    Jacksonville, Florida · Recruiting

  • Alkermes Investigational Site

    Lakeland, Florida · Recruiting

  • Alkermes Investigational Site

    Largo, Florida · Recruiting

  • Alkermes Investigational Site

    Maitland, Florida · Recruiting

  • Alkermes Investigator Site

    Maitland, Florida · Recruiting

  • Alkermes Investigational Site

    Maitland, Florida · Recruiting

  • Alkermes Investigational Site

    Orange City, Florida · Recruiting

  • Alkermes Investigational Site

    Orlando, Florida · Recruiting

  • Alkermes Investigational Site

    Tampa, Florida · Recruiting

  • Alkermes Investigational Site

    Decatur, Georgia · Recruiting

  • Alkermes Investigational Site

    Foxborough, Massachusetts · Recruiting

  • Alkermes Investigational Site

    Watertown, Massachusetts · Recruiting

  • Alkermes Investigational Site

    Detroit, Michigan · Recruiting

  • Alkermes Investigational Site

    Lincoln, Nebraska · Recruiting

  • Alkermes Investigational Site

    Las Vegas, Nevada · Recruiting

  • Alkermes Investigational Site

    Las Vegas, Nevada · Recruiting

  • Alkermes Investigational Site

    North Canton, Ohio · Recruiting

  • Alkermes Investigational Site

    East Providence, Rhode Island · Recruiting

  • Alkermes Investigational Site

    North Charleston, South Carolina · Recruiting

  • Alkermes Investigational Site

    Memphis, Tennessee · Recruiting

  • Alkermes Investigational Site

    Austin, Texas · Recruiting

  • Alkermes Investigational Site

    Austin, Texas · Recruiting

  • Alkermes Investigational Site

    The Woodlands, Texas · Recruiting

  • Alkermes Investigational Site

    Bellevue, Washington · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.